NNI seeks to ameliorate neurodegeneration seen in Alzheimer's disease and other dementias. Toward this end, NNI scientists have targeted neurofibrillary tangle (NFT) formation for drug discovery. These lesions appear in concert with the onset of memory loss in AD, and are in fact the best markers for AD neurodegeneration known in the scientific literature. Thus NNI has pursued agents that interfere with NFT formation. As part of Phase I effort, the feasibility of inhibiting tau filament formation and driving filament depolymerization in vitro using small, drug-like ligands was demonstrated. Moreover, the ability of one such molecule to halt progression of neurodegeneration in an animal model of disease was shown. The goal of Phase II effort is to extend these results by validating tau fibrillization as a drug target, and proving that in vitro screening technology can successfully identify compounds that are active in animal models of tau-induced neurodegeneration. There are three Aims. First, NNI will expand its screening effort to identify additional classes of molecules with anti tau polymerization activity. NNI has shown the feasibility of using its screening technology to identify such molecules. Second, NNI will characterize the mechanism of action of its compounds, establishing a structure activity relationship for members of the existing structural family. Finally, NNI will examine the activity of active compounds in vivo, demonstrating entry into the brain, and determining a structure activity relationship for in vivo activity. At the end of the project, NNI will be in position to establish neuritic lesions (e.g., NFTs) as an authentic target for intensive preclinical development.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AG018661-02
Application #
6645105
Study Section
Special Emphasis Panel (ZRG1-MDCN-3 (10))
Program Officer
Buckholtz, Neil
Project Start
2000-07-01
Project End
2005-01-01
Budget Start
2003-08-01
Budget End
2004-07-31
Support Year
2
Fiscal Year
2003
Total Cost
$403,824
Indirect Cost
Name
Neuronautics, Inc.
Department
Type
DUNS #
361521748
City
Evanston
State
IL
Country
United States
Zip Code
60201
Kim, Wonhee; Lee, Sangmook; Jung, Cheolwha et al. (2010) Interneuronal transfer of human tau between Lamprey central neurons in situ. J Alzheimers Dis 19:647-64
Honson, Nicolette S; Jensen, Jordan R; Abraha, Aida et al. (2009) Small-molecule mediated neuroprotection in an in situ model of tauopathy. Neurotox Res 15:274-83